For Patients
Partnerships for Hereditary Spastic Paraplegia (HSP)
Cure AP-4
Cure AP-4 aims to improve the quality of life for children impacted by AP-4 Related Hereditary Spastic Paraplegia (AP-4 HSP) by accelerating the research for cures and treatments and providing support for patient therapies critical to their well-being and rehabilitation. The ultimate goal of this organization is to study and discover a cure for all AP-4 HSP disorders (SPG47, SPG50, SPG51 and SPG52).
Cure SPG50
The goal of Cure SPG50 is to create a cure for SPG50. Current efforts are focused on exploration of gene therapy through sponsorship of research and development with scientists, labs, and hospitals around the world.
CLINICAL TRIAL
Registry and Natural History Study for Early Onset Hereditary Spastic Paraplegia (HSP)
PI: Darius Ebrahimi-Fakhari, MD, PhD | Registry and Natural History Study — NCT04712812 >
Patient Advocacy Group Partners: CureAP4, Cure SPG50